IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021PRNewsWire • 04/19/21
IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal MelanomaPRNewsWire • 04/16/21
IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal MelanomaPRNewsWire • 04/15/21
IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid TumorsPRNewsWire • 04/15/21
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/23/21
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business UpdatePRNewsWire • 03/23/21
IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical ActivityPRNewsWire • 03/23/21
IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196PRNewsWire • 03/11/21
IDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical AffairsPRNewsWire • 02/08/21
IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDAPRNewsWire • 01/11/21
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET InhibitorPRNewsWire • 01/05/21
IDEAYA to Participate in Upcoming January 2021 Investor Relations Events and Scientific ConferencesPRNewsWire • 01/04/21
IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business UpdatePRNewsWire • 11/12/20
IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And PlatformPRNewsWire • 10/22/20
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 MutationsPRNewsWire • 09/24/20
IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business UpdatePRNewsWire • 08/12/20